Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival by McArdle, Colin S et al.
RESEARCH ARTICLE Open Access
Adjuvant radiotherapy and chemotherapy in
breast cancer: 30 year follow-up of survival
Colin S McArdle
1, Donald C McMillan
1, Nicola Greenlaw
2, David S Morrison
2*
Abstract
Background: The long term outcome (more than 15 years) of adjuvant treatment in patients with primary
operable breast cancer has rarely been examined.
Methods: A randomised clinical trial of radiotherapy, chemotherapy (28 day cycles of cyclophosphamide,
methotrexate and 5-fluorouracil) or both on women with primary operable breast cancer (n = 322) was followed-
up for a median of 27 years.
Results: 260 (81%) patients died, 204 (78%) from breast cancer. Cancer specific survival (SE) at 10 years, 20 years
and 30 years was 41 (3)%, 34 (3)% and 33 (3)% respectively. Presence of more than 3 involved lymph nodes
increased cancer-specific mortality (HR 1.88, 95% CI 1.34-2.63) after adjustment for age, socio-economic deprivation
and adjuvant treatment. Both age (HR 1.63, 95% CI 1.19-2.22) and involved lymph nodes (HR 1.59, 95% CI 1.17-2.14)
were significant predictors of all-cause mortality after adjustment for other factors. There was no significant
difference in all-cause or cancer-specific survival between patients in each of the 3 treatment arms.
Conclusions: The present study highlights the long term impact of node positive disease but does not indicate
that any regimen was associated with significantly better long-term survival.
Background
Breast cancer is the commonest malignancy in females
and is a major cause of morbidity and mortality in the
Western World[1]. Prior to the introduction of che-
motherapy the mainstay of treatment was based on sur-
gery and radiotherapy. A series of clinical trials started
in the mid 1970 s, with approximately 5 years’ follow-
up, established the role of chemotherapy as an adjuvant
treatment for primary operable breast cancer[2-5].
In contrast, the long term outcome of such adjuvant
treatment in these patients is less clear. Recently, Bona-
donna and co-workers[6] reported that, after follow-up
of 30 years, adjuvant cyclophosphamide, methotrexate,
and fluorouracil (CMF) was associated with a persistent
reduction in overall mortality of approximately 20%
compared with surgery alone. However, to our knowl-
edge, there have been no reports that compare long
term survival in patients receiving CMF with two of the
commonest alternative regimens for primary operable
breast cancer, CMF combined with radiotherapy and
radiotherapy alone[3].
The aim the present study was therefore to establish
long term outcome in women receiving adjuvant radio-
therapy and chemotherapy as part of a randomised trial.
Methods
The study design has been previously described[3].
Briefly, between June 1976 and December 1982 women
aged 70 years or less admitted to three teaching hospi-
tals, with operable breast cancer and with no evidence
of metastatic disease, were entered into the study.
Women with histological involvement of the axillary
nodes were randomized to receive either: conventional
postoperative radiotherapy, chemotherapy alone or
radiotherapy followed by chemotherapy. The che-
motherapy regimen was based on that described by
Bonadonna - consecutive 28 day cycles of cyclophospha-
mide, methotrexate and 5-fluorouracil[2].
Information on date and cause of death was obtained
through Scottish Cancer Registry patient-based linkage
with the General Register Office for Scotland (GRO(S))
death records. Deaths up to the end of 30
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median length of follow-up of 27 years (minimum 25
years, maximum 31 years). Cancer-specific survival was
calculated using all deaths in which the principal cause
of death was recorded as breast cancer (International
Classification of Diseases, Revision 9, 174 and 199; ICD-
10 C50). Socio-economic deprivation was inferred for
each patient using the DEPCAT score[7] associated with
their postcode of residence. The DEPCAT is a validated
7-category score that ranks all postcode areas from 1
(most affluent) to 7 (most deprived) using four Census
variables shown best to correlate with health outcomes:
car ownership; overcrowding; proportion of population
in occupational Social Classes IV and V; and male
unemployment. We further grouped DEPCATs into 3
conventional classes: DEPCATs 1 and 2 (affluent); 3 to
5 (intermediate); and 6 and 7 (deprived).
Statistics
Cumulative survival after mastectomy was estimated
using the Kaplan-Meier method and the logrank used to
test for independence between treatment groups. The
grouping of variables was carried out using standard
thresholds. Life tables showing cancer-specific survival
and associated standard errors were calculated using
SPSS version 15 software. Univariate and multivariate
survival analysis and calculation of hazard ratios (HRs)
were carried out using Cox’s proportional-hazards
model. Analysis was carried out using STATA version
10 statistical software. Multivariate analyses were strati-
fied by oestrogen receptor status in order to satisfy the
proportionality assumption, which was tested using the
calculated Schoenfeld residuals and the scaled Schoen-
feld residuals[8]. These residuals are used to test the
null hypothesis that the log hazard-ratio function is con-
stant over time, that is, that the ratio of hazards between
different groups (for example, between patients aged 50
or less and over-50) is constant over time.
Results
Three hundred and twenty-two patients were included
in the study. One hundred and three patients were allo-
cated to receive radiotherapy alone, 111 sequential
radiotherapy and chemotherapy and 108 chemotherapy
alone. The incidence of unfavourable prognostic fea-
tures, such as age, deprivation, tumour size, involved
lymph nodes, and oestrogen receptor status, was similar
between the groups.
After 30 years’ follow-up 260 (81%) died; of these 204
(78%) died of breast cancer. Cancer specific survival
(SE) at 10 years, 20 years and 30 years was 41 (3)%, 34
(3)% and 33 (3)% respectively. All-cause survival (SE) at
10 years, 20 years and 30 years was 37 (3)%, 23 (2)%
and 19 (2)% respectively. There was a trend towards
improved cancer-specific survival in the sequential
radiotherapy and chemotherapy arm but no overall dif-
ference in either breast cancer-specific (Figure 1, logrank
p = 0.090) or all-cause survival (p = 0.154) between
groups.
The relationships between clinicopathological features
and treatment and both cancer-specific and overall
survival at 30 years are shown in Table 1. Age over
50 years, and more than 3 involved lymph nodes, were
associated with significantly poorer cancer-specific and
all-cause survival. Formally defined post-menopausal
status was associated with poorer overall survival but
not with cancer-specific survival.
The relationships between clinicopathological features,
treatment and both cancer-specific and overall survival
were explored by multivariate proportional hazards ana-
lyses and results shown in Table 2. Increasing age
(p = 0.018) and involved numbers of lymph nodes
(p < 0.001) were associated with poorer cancer specific
survival in univariate analysis. On multivariate analysis,
shown in Table 2, only involved lymph nodes (HR 1.88,
95% CI 1.34-2.63) remained significant determinants of
cancer-specific survival. Both age (HR 1.63, 95%
CI 1.19-2.22) and involved lymph nodes (HR 1.59, 95%
CI 1.17-2.14) were significant predictors of all-cause
mortality after adjustment for other factors. There was
no significant difference in all-cause or cancer-specific
survival between patients in each of the 3 treatment
arms. There were no significant interactions between
survival from each of the 3 treatment modalities and
age, deprivation or number of involved lymph nodes.
Discussion
In the present study there was an approximate 80%
reduction in 30 year cancer-specific survival in those
patients with 4 or more involved lymph nodes. In con-
trast, there was no significant impact of treatment mod-
ality on long term cancer survival. Therefore, the
present study confirms the long term impact of node
positive disease but does not indicate that any regimen
was associated with significantly better long-term
survival.
The results of the present study are therefore consis-
tent with our previous report of the 5 year results of
this randomised trial comparing adjuvant radiotherapy,
radiotherapy and chemotherapy and chemotherapy
alone in women with primary operable breast cancer[3].
The main findings then were that the combination of
radiotherapy and chemotherapy was associated with
reduced recurrence and a trend towards increased
cancer-specific survival; and that disease-related survival
was mainly dependent on the number of positive nodes.
The present results are also consistent with other
reports which indicate that while radiotherapy reduces
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effect on mortality at 20 years (although Rutqvist also
reported that chemotherapy was associated with longer
recurrence-free survival among premenopausal women
only)[10]. A meta-analysis suggests that the modest ben-
efits of radiotherapy on breast cancer specific mortality
are offset by increased mortality from other causes[11].
While Fisher and others’ trial[12] - which began in the
same year as the present study - found that the addition
of radiotherapy to segmental mastectomy conferred a
significant survival advantage, it may be that longer-
term follow-up would also have shown increased
Figure 1 The relationship between treatment (radiotherapy and chemotherapy/radiotherapy/chemotherapy from top to bottom) and
cancer specific survival in patients with primary operable breast cancer with 30 year follow-up.
Table 1 30-year cancer specific and overall cumulative survival for patients undergoing adjuvant radiotherapy and
chemotherapy with primary operable breast cancer, n = 322
Cancer-specific
survival
p-value Overall
survival
p-value
Age
≤50 years 40 (5) 0.023 31 (2) 0.001
>50 years 28 (3) 12 (2)
Socio-economic circumstances
Affluent (DEPCATs 1-2) 41 (6) 24 (5)
Intermediate (DEPCATs 3-5) 33 (4) 0.657 19 (3) 0.784
Deprived (DEPCATs 6-7) 27 (5) 14 (4)
Menopausal status
Pre 39 (4) 0.071 30 (4) 0.002
Post 29 (4) 12 (2)
Involved lymph node
≤3 38 (4) <0.001 21 (3) <0.001
>3 23 (4) 14 (3)
Hormonal-receptor status
ER+ 33 (5) 0.052 17 (4) 0.055
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ferences in surgical interventions between treatment
arms - a choice of breast conserving surgery of mastect-
omy - would have influenced long-term survival[13-15].
A systematic review of chemotherapy trials for breast
cancer found that adjuvant polychemotherapy reduced
mortality in postmenopausal women by 2% and 6% in
node negative and node positive women, respectively
[16]. However, the observed effect may have been be
due to the additional benefits of tamoxifen on long-term
survival[17] and the drug was not available in the
United Kingdom at the start of the present study.
The present study has a number of limitations, princi-
p a l l yt h a tw ed i dn o th a v ed a t ao nt u m o u rg r a d ew i t h
which we might have been able to calculate the Notting-
ham Prognostic Index[18] nor did we have more
detailed data on doses and compliance with each treat-
ment modality. Death records may be susceptible to
coding errors and misclassification of the cause of death
might have either increased or decreased the true cause-
specific mortality. The lack of statistically significant dif-
ferences in survival between treatment arms may be due
to insufficient numbers of patients; it may reflect a true
absence of effect; or unidentified confounding factors
may have obscured a true difference. Nevertheless, the
major strength of the present study is the duration of
follow up, which, with the exception of the study by
Bonadonna[2], is to our knowledge the longest reported.
Conclusions
Although there have been advances in the surgical, radi-
ological and chemotherapeutic treatment of primary
operable breast cancer over the past 30 years the pre-
sent results highlight the long lasting detrimental effect
of node positive disease. Our analysis describes the
impact of the first adjuvant regimens but does not indi-
cate that any regimen was associated with significantly
better long-term survival.
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